Immune correlates of HIV-1 reservoir cell decline in early-treated infants.

Antiviral Agents / therapeutic use CD4-Positive T-Lymphocytes HIV Infections HIV Seropositivity HIV-1 Humans Immunity, Innate Infant, Newborn Killer Cells, Natural
CP: Immunology CP: Microbiology HIV reservoir NK cells innate immune responses intact HIV-1 proviruses pediatric HIV-1 infection

Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
19 07 2022
Historique:
received: 13 12 2021
revised: 13 04 2022
accepted: 30 06 2022
entrez: 20 7 2022
pubmed: 21 7 2022
medline: 23 7 2022
Statut: ppublish

Résumé

Initiation of antiretroviral therapy (ART) in infected neonates within hours after birth limits viral reservoir seeding but does not prevent long-term HIV-1 persistence. Here, we report parallel assessments of HIV-1 reservoir cells and innate antiviral immune responses in a unique cohort of 37 infected neonates from Botswana who started ART extremely early, frequently within hours after birth. Decline of genome-intact HIV-1 proviruses occurs rapidly after initiation of ART and is associated with an increase in natural killer (NK) cell populations expressing the cytotoxicity marker CD57 and with a decrease in NK cell subsets expressing the inhibitory marker NKG2A. Immune perturbations in innate lymphoid cells, myeloid dendritic cells, and monocytes detected at birth normalize after rapid institution of antiretroviral therapy but do not notably influence HIV-1 reservoir cell dynamics. These results suggest that HIV-1 reservoir cell seeding and evolution in early-treated neonates is markedly influenced by antiviral NK cell immune responses.

Identifiants

DOI: 10.1016/j.celrep.2022.111126 PMID: 35858580 PMC: PMC9314543
pubmed: 35858580
pii: S2211-1247(22)00932-9
doi: 10.1016/j.celrep.2022.111126
pmc: PMC9314543
pii:
doi:

Substances chimiques

Antiviral Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Intramural Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

111126

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI078799
Pays : United States
Organisme : NIAID NIH HHS
ID : K24 AI155233
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI135940
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL134539
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI114235
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI098487
Pays : United States
Organisme : NIDA NIH HHS
ID : R61 DA047034
Pays : United States
Organisme : NIAID NIH HHS
ID : R33 AI116228
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI120850
Pays : United States
Organisme : NIDA NIH HHS
ID : R33 DA047034
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI152979
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI117841
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK120387
Pays : United States
Organisme : NIAID NIH HHS
ID : R56 AI125109
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI120008
Pays : United States
Organisme : CCR NIH HHS
ID : HHSN261200800001C
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI116228
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI164566
Pays : United States

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests D.R.K. has received consulting honoraria and/or research support from Gilead, Merck, and ViiV. M.L. has received speaking and consulting honoraria from Merck.

Références

Lancet HIV. 2018 Dec;5(12):e706-e714
pubmed: 30416043
J Clin Invest. 2013 Sep;123(9):3889-901
pubmed: 23945237
Science. 2017 Apr 21;356(6335):
pubmed: 28428369
Proc Biol Sci. 2015 Dec 22;282(1821):20143085
pubmed: 26702035
Sci Transl Med. 2020 May 13;12(543):
pubmed: 32404504
Retrovirology. 2012 Dec 20;9:113
pubmed: 23256516
BMC Public Health. 2019 Jan 28;19(1):115
pubmed: 30691416
Bioinformatics. 2000 Apr;16(4):400-1
pubmed: 10869039
PLoS Pathog. 2021 Nov 18;17(11):e1010090
pubmed: 34793581
Science. 2018 Jan 5;359(6371):86-90
pubmed: 29302013
Mol Biol Evol. 2018 Jun 1;35(6):1547-1549
pubmed: 29722887
N Engl J Med. 2015 Feb 19;372(8):786-8
pubmed: 25693029
Clin Infect Dis. 2012 Feb 1;54(3):434-42
pubmed: 22247303
Clin Infect Dis. 2022 Mar 23;74(6):1047-1054
pubmed: 34185838
J Clin Invest. 2017 Jun 30;127(7):2689-2696
pubmed: 28628034
Cell Rep. 2017 Oct 17;21(3):813-822
pubmed: 29045846
Nat Commun. 2019 Jan 24;10(1):412
pubmed: 30679439
J Immunol. 2020 Feb 1;204(3):540-549
pubmed: 31889024
PLoS Biol. 2007 Jul;5(7):e177
pubmed: 17594176
Annu Rev Immunol. 2020 Apr 26;38:229-247
pubmed: 31928469
Nat Commun. 2019 Jun 21;10(1):2737
pubmed: 31227699
Cell Host Microbe. 2019 Aug 14;26(2):296
pubmed: 31415756
J Clin Invest. 2019 Mar 12;129(5):2094-2106
pubmed: 30860984
Lancet. 2021 Apr 3;397(10281):1316-1324
pubmed: 33812490
J Exp Med. 1997 Feb 17;185(4):795-800
pubmed: 9034158
Nat Med. 2009 Aug;15(8):893-900
pubmed: 19543283
Sci Transl Med. 2014 May 21;6(237):237ra65
pubmed: 24848255
AIDS. 2017 Jun 1;31(9):1344-1346
pubmed: 28492397
Blood. 2003 Aug 15;102(4):1428-34
pubmed: 12714521
J Clin Virol. 2013 Sep;58(1):74-8
pubmed: 23727304
Pediatr Infect Dis J. 2020 Feb;39(2):127-133
pubmed: 31725119
J Infect Dis. 2021 Jul 2;224(1):92-100
pubmed: 33216132
Nat Biotechnol. 2007 Dec;25(12):1407-10
pubmed: 18066037
J Clin Invest. 2021 Feb 1;131(3):
pubmed: 33301425
J Immunol. 1997 Apr 15;158(8):3603-9
pubmed: 9103421
Lancet HIV. 2016 Jan;3(1):e49-54
pubmed: 26762993
JCI Insight. 2020 Feb 27;5(4):
pubmed: 32045386
EClinicalMedicine. 2020 Jan 07;18:100241
pubmed: 31993578
Genome Biol. 2018 Jan 29;19(1):10
pubmed: 29378643
Immunity. 2017 Oct 17;47(4):776-788.e5
pubmed: 29045906
Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):11970-5
pubmed: 23818644
J Biol Chem. 1999 Nov 26;274(48):34089-95
pubmed: 10567377
Science. 2015 May 22;348(6237):aaa6566
pubmed: 25999512
Cytometry A. 2015 Jul;87(7):636-45
pubmed: 25573116
J Clin Invest. 2019 Mar 1;129(3):988-998
pubmed: 30688658
Blood. 2010 Nov 11;116(19):3865-74
pubmed: 20733159
Sci Transl Med. 2019 Nov 27;11(520):
pubmed: 31776292
J Exp Med. 2020 Jul 6;217(7):
pubmed: 32311008
J Clin Invest. 2021 May 3;131(9):
pubmed: 33938445
J Infect Dis. 2021 Feb 3;223(2):225-233
pubmed: 32823274
Clin Infect Dis. 2021 Feb 1;72(3):388-393
pubmed: 31927562
AIDS. 2014 Apr 24;28(7):1015-20
pubmed: 24384692
Clin Exp Immunol. 2013 Dec;174(3):414-23
pubmed: 23952339
Lancet HIV. 2018 May;5(5):e250-e258
pubmed: 29739699
Sci Transl Med. 2021 Jun 23;13(599):
pubmed: 34162752
Nucleic Acids Res. 2004 Mar 19;32(5):1792-7
pubmed: 15034147

Auteurs

Ciputra Adijaya Hartana (CA)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA.

Pilar Garcia-Broncano (P)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA.

Yelizaveta Rassadkina (Y)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.

Xiaodong Lian (X)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA.

Chenyang Jiang (C)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA.

Kevin B Einkauf (KB)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.

Kenneth Maswabi (K)

Botswana - Harvard AIDS Institute Partnership, Gaborone, Botswana.

Gbolahan Ajibola (G)

Botswana - Harvard AIDS Institute Partnership, Gaborone, Botswana.

Sikhulile Moyo (S)

Botswana - Harvard AIDS Institute Partnership, Gaborone, Botswana.

Terence Mohammed (T)

Botswana - Harvard AIDS Institute Partnership, Gaborone, Botswana.

Comfort Maphorisa (C)

Botswana - Harvard AIDS Institute Partnership, Gaborone, Botswana.

Joseph Makhema (J)

Botswana - Harvard AIDS Institute Partnership, Gaborone, Botswana.

Yuko Yuki (Y)

Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD 20892, USA; Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.

Maureen Martin (M)

Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD 20892, USA; Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.

Kara Bennett (K)

Bennett Statistical Consulting, Inc., Ballston Lake, NY 12019, USA.

Patrick Jean-Philippe (P)

Division of AIDS, NIAID, NIH, Rockville, MD 20852, USA.

Mathias Viard (M)

Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD 20892, USA; Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.

Michael D Hughes (MD)

Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.

Kathleen M Powis (KM)

Harvard Medical School, Boston, MA 02115, USA; Botswana - Harvard AIDS Institute Partnership, Gaborone, Botswana; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA; Department of Medicine and Pediatrics, Massachusetts General Hospital, Boston, MA 02114, USA.

Mary Carrington (M)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD 20892, USA; Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.

Shahin Lockman (S)

Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA; Botswana - Harvard AIDS Institute Partnership, Gaborone, Botswana.

Ce Gao (C)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.

Xu G Yu (XG)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA.

Daniel R Kuritzkes (DR)

Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA.

Roger Shapiro (R)

Harvard Medical School, Boston, MA 02115, USA; Botswana - Harvard AIDS Institute Partnership, Gaborone, Botswana; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.

Mathias Lichterfeld (M)

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA. Electronic address: mlichterfeld@partners.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antiviraux › Immune correlates of HIV-1 reservoir cell...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD4+ › Immune correlates of HIV-1 reservoir cell...
questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à VIH › Immune correlates of HIV-1 reservoir cell...
questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à VIH › Séropositivité VIH › Immune correlates of HIV-1 reservoir cell...
questionsmedicales.fr › Virus › Virus à ARN › Retroviridae › Lentivirus › Lentivirus des primates › VIH (Virus de l'Immunodéficience Humaine) › VIH-1 (Virus de l'Immunodéficience Humaine de type 1) › Immune correlates of HIV-1 reservoir cell...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Immune correlates of HIV-1 reservoir cell...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Immunité innée › Immune correlates of HIV-1 reservoir cell...
questionsmedicales.fr › Personnes › Tranches d'âge › Nourrisson › Nouveau-né › Immune correlates of HIV-1 reservoir cell...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Cellules tueuses naturelles › Immune correlates of HIV-1 reservoir cell...